Patents Examined by Andrea McCollum
-
Patent number: 9873739Abstract: The disclosure relates to compositions and methods of mitigating tissue damage and fibrosis in a patient by modulating latent transforming growth factor beta binding protein (LTBP4)-induced proteolysis of a Transforming Growth Factor-beta (TGF?) superfamily protein.Type: GrantFiled: August 1, 2013Date of Patent: January 23, 2018Assignee: Ikaika Therapeutics, LLCInventors: Elizabeth McNally, Ahlke Heydemann, Ermelinda Ceco
-
Patent number: 9845359Abstract: The invention provides FGFR1 agonists, including agonistic anti-FGFR1 antibodies, and methods of using the same.Type: GrantFiled: June 29, 2015Date of Patent: December 19, 2017Assignee: Genentech, Inc.Inventors: Junichiro Sonoda, Yan Wu
-
Patent number: 9822170Abstract: Epidermal growth factor receptor (EGFR) expression and phosphorylation is increased in cancer cells treated with anti-clusterin antibodies. Such treatment is also accompanied with the reappearance of an epithelial phenotype of the cancer cell, as determined by an increased E-cadherin expression at the surface of cancer cells. Clusterin inhibitors may thus induce reversal of the epithelial to mesenchymal phenotype and restore sensitivity of cancer cells to EGFR inhibitors. Combinations of a clusterin inhibitor and an EGFR as well as their use in treatment of cancer are thus provided herewith.Type: GrantFiled: February 22, 2013Date of Patent: November 21, 2017Assignee: Alethia Biotherapeutics Inc.Inventors: Gilles Bernard Tremblay, Elisabeth Viau, Mario Filion
-
Patent number: 9821028Abstract: Disclosed herein are methods of controlling parasitic worms in herbivorous mammals and other species by orally administering an isolated antibody that specifically binds the interleukin-10 peptide or an interleukin-10 peptide. In the case of herbivorous mammals such as cattle, for example, administration of the anti-IL-10 antibodies increases weight gain and increases feed efficiency in the animals.Type: GrantFiled: July 11, 2014Date of Patent: November 21, 2017Assignee: WISCONSIN ALUMNI RESEARCH FOUNDATIONInventors: Mark Eric Cook, Daniel Meilahn Schaefer, Mitchell Raymond Schaefer, Jordan Marshall Sand, Larry Smith
-
Patent number: 9822176Abstract: Novel anti-interleukin 3 (IL-3) antibodies or fragments or constructs thereof according to the present invention specifically bind to an epitope contained within the N-terminal 20 amino acids of the amino acid sequence of human IL-3 according to SEQ ID No. 1, and preferably to a sequence motif SWVN (SEQ ID NO: 2). The antibodies can be used in diagnostic methods for the determination of IL-3 levels in body fluids, preferably in corresponding ELISA assays, but also in pharmaceutical compositions for the treatment or prevention of diseases which are associated with elevated levels of IL-3 in a patient, especially rheumatoid arthritis.Type: GrantFiled: May 29, 2013Date of Patent: November 21, 2017Assignee: UNIVERSITÄTSKLINIKUM REGENSBURGInventors: Matthias Mack, Hilke Brühl, Kerstin Renner
-
Patent number: 9821029Abstract: Described herein are methods of reducing Salmonella in the intestines of poultry in need thereof by administering to a poultry bird an effective amount of an interleukin-10 peptide or an isolated antibody that specifically binds an interleukin-10 peptide. Administering may be performed within 1 to 4 weeks of harvest of the poultry in order to reduce Salmonella transmission to human consumers. Also included herein are finishing feeds that include an interleukin-10 peptide or an isolated antibody that specifically binds an interleukin-10 peptide.Type: GrantFiled: July 16, 2015Date of Patent: November 21, 2017Assignees: WISCONSIN ALUMNI RESEARCH FOUNDATION, THE UNITED STATES OF AMERICA AS REPRESENTED BY THE SECRETARY OF AGRICULTUREInventors: Mark Eric Cook, Jordan Marshall Sand, Mike H. Kogut, Christina L. Swaggerty
-
Patent number: 9814758Abstract: The invention relates to fragments of the Death-Domain Associated protein (DAXX protein) and of the Fas-Associated Death Domain protein (FADD protein) that inhibit cell apoptosis, in particular cell apoptosis mediated by the Fas receptor. The invention also relates to derivatives of said anti-apoptotic fragments, conjugates comprising said fragments, pharmaceutical compositions comprising said fragments, and to the medical applications of said fragments, derivatives, conjugates, and pharmaceutical compositions thereof in the treatment or prevention of diseases and conditions associated with apoptosis.Type: GrantFiled: November 17, 2011Date of Patent: November 14, 2017Assignees: CENTRE NATIONAL DE LA RECHERCHE SCIENTIFIQUE-CNRS, UNIVERSITE MONTPELLIER 2-SCIENCES ET TECHNIQUE, UNIVERSITE DE MONTPELLIER 1Inventors: Stéphanie Barrere, Joël Nargeot, Bernard Lebleu, Prisca Boisguerin, Christophe Piot
-
Patent number: 9783574Abstract: Compounds and compositions comprising a B-type natriuretic signal peptide fragment agent, and methods of use thereof, are provided for the treatment or prevention of cardiovascular diseases, disorders, and conditions.Type: GrantFiled: August 17, 2012Date of Patent: October 10, 2017Assignee: Otago Innovation LimitedInventors: Christopher Joseph Pemberton, Arthur Mark Richards, Christopher John Charles, Maithri Siriwardena
-
Patent number: 9763866Abstract: The invention provides for methods for treating a hair loss disorder in a subject by administering a Janus Kinase/Signal Transducers and Activators of Transcription inhibitor.Type: GrantFiled: March 10, 2016Date of Patent: September 19, 2017Assignee: THE TRUSTEES OF COLUMBIA UNIVERSITY IN THE CITY OF NEW YORKInventors: Angela M. Christiano, Raphael Clynes
-
Patent number: 9765140Abstract: An Interleukin-17 (IL-17) binding molecule, in particular an antibody to human IL-17, more preferably a human antibody to human IL-17 is provided, wherein the hypervariable regions of the heavy and light chains have amino acid sequences as defined, for use in the treatment of an IL-17 mediated disease or disorder, e.g. rheumatoid arthritis.Type: GrantFiled: February 18, 2015Date of Patent: September 19, 2017Assignee: Novartis AGInventors: Franco E Di Padova, Hermann Gram, Hans Hofstetter, Margit Jeschke, Jean-Michel Rene Rondeau, Wim Van Den Berg
-
Patent number: 9757469Abstract: Polyethylene glycol modified human chorionic gonadotropin (hCG), preparations thereof, compositions thereof, and methods of preparation and use thereof are described.Type: GrantFiled: March 29, 2012Date of Patent: September 12, 2017Assignee: Ferring B.V.Inventors: Ian Cottingham, Daniel Plaksin, Jenny Aharanov
-
Patent number: 9737469Abstract: The invention provides for methods for treating a hair loss disorder in a subject by administering a Janus Kinase/Signal Transducers and Activators of Transcription inhibitor.Type: GrantFiled: March 10, 2016Date of Patent: August 22, 2017Assignee: The Trustees of Columbia University in the City of New YorkInventors: Angela M. Christiano, Raphael Clynes
-
Patent number: 9730877Abstract: The invention provides for methods for treating a hair loss disorder in a subject by administering a Janus Kinase/Signal Transducers and Activators of Transcription inhibitor.Type: GrantFiled: August 7, 2015Date of Patent: August 15, 2017Assignee: The Trustees of Columbia University in the City of New YorkInventors: Angela M. Christiano, Raphael Clynes
-
Patent number: 9732151Abstract: The present invention relates to biomarker responsive to treatment with an anti-Thymic Stromal Lymphopoietin (TSLP) antibody.Type: GrantFiled: October 31, 2012Date of Patent: August 15, 2017Assignee: Merck Sharp & Dohme Corp.Inventors: Maribel Beaumont, Jeanine D. Mattson, Jennifer R. Louten, Terrill K. McClanahan, Rene de Waal Malefyt
-
Patent number: 9724412Abstract: The disclosure relates to chymase, antibodies to chymase, and diagnostic and therapeutic methods relates thereto. It has been discovered that above certain circulating levels of chymase, a patient has a high likelihood of arteriovenous fistula nonmaturation. Compositions and methods of detecting and measuring chymase levels are disclosure herein. In certain embodiments, the disclosure relates to methods of determining the effectiveness of creating an arteriovenous fistula in a subject diagnosed with chronic kidney disease.Type: GrantFiled: July 11, 2012Date of Patent: August 8, 2017Assignee: Emory UniversityInventors: Haimanot Wasse, Ahsan Husain, Nawazish Ali Naqvi
-
Patent number: 9719996Abstract: The invention provides anti-mesothelin antibodies and immunoconjugates and methods of using the same.Type: GrantFiled: November 12, 2014Date of Patent: August 1, 2017Assignee: GENENTECH, INC.Inventors: Mark Dennis, Suzanna J. Scales, Susan D. Spencer, Yin Zhang
-
Patent number: 9708410Abstract: Isolated anti-tissue factor antibodies, immunoglobulins, cleavage products and other specified portions and variants thereof having enhanced ADCC activity, as well as anti-tissue factor antibody compositions, encoding or complementary nucleic acids, vectors, host cells, compositions, formulations, devices, transgenic animals, transgenic plants, and methods of making and using thereof. The antibodies of the invention bind human tissue factor and demonstrate enhanced ADCC activity. Accordingly, the antibodies can be used in a variety of methods for diagnosing, treating, and/or preventing diseases involving tissue factor, where enhanced ADCC activity is desirable such as cancer.Type: GrantFiled: September 20, 2012Date of Patent: July 18, 2017Assignee: Janssen Biotech, Inc.Inventors: G. Mark Anderson, Bernard Scallon, Michael Naso, Ann Cai, Cam Holland
-
Patent number: 9688763Abstract: The present invention relates to polypeptides directed against or specifically binding to chemokine receptor CXCR2 and in particular to polypeptides capable of modulating signal transduction from CXCR2. The invention also relates to nucleic acids, vectors and host cells capable of expressing the polypeptides of the invention, pharmaceutical compositions comprising the polypeptides and uses of said polypeptides and compositions for treatment of diseases involving aberrant functioning of CXCR2.Type: GrantFiled: June 26, 2015Date of Patent: June 27, 2017Assignee: Novartis AGInventors: Zarin Brown, Michelle Bradley, Steven John Charlton, Gino Anselmus Van Heeke, Karen Cromie, Bruno Dombrecht, Soren Steffensen, Judith Baumeister, Marie-Paule Bouche, Carlo Boutton, Marie-Ange Buyse, Veerle Snoeck, Stephanie Staelens
-
Patent number: 9683998Abstract: The present invention provides antibodies, or antigen-binding fragment thereof, which specifically bind to tumor necrosis factor-like ligand 1A (TL1A). The invention further provides a method of obtaining such antibodies and nucleic acids encoding the same. The invention further relates to compositions and therapeutic methods for use of these antibodies for the treatment and/or prevention of TL1A mediated diseases, disorders or conditions.Type: GrantFiled: November 12, 2014Date of Patent: June 20, 2017Assignees: Pfizer Inc., Bristol-Myers Squibb CompanyInventors: Robert Arch, Jun Zhang, Michelle Madar, Tetsuya Ishino, Joel Bard, William Finlay, Orla Cunningham, Ciara Reilly, Peter Brams, Brigitte Devaux, Haichun Huang, Karla Henning
-
Patent number: 9676835Abstract: The present disclosure describes recombinant human chorionic gonadotropin (hCG) and methods for the production thereof. The recombinant hCG can include ?2,3, ?2,6, and, optionally, ?2,8 sialylation. The recombinant hCG can be produced in a human cell line such as a PER.C6® cell line.Type: GrantFiled: May 21, 2014Date of Patent: June 13, 2017Assignee: Ferring B.V.Inventors: Ian Cottingham, Daniel Plaksin, Richard Boyd White